Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTAI NASDAQ:EXOZ NASDAQ:IGMS OTCMKTS:NICXF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$4.05-1.2%$2.97$1.17▼$13.36$65.64M0.0528.20 million shs2.70 million shsEXOZeXoZymes$9.70$9.86$8.50▼$23.99$81.36MN/A1,215 shs331 shsIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/ANICXFNicox$0.30$0.28$0.25▼$0.30$20.67M0.33N/AN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics-1.22%-18.67%+183.22%+243.22%-58.15%EXOZeXoZymes0.00%+4.19%-3.96%-27.67%+969,999,900.00%IGMSIGM Biosciences0.00%0.00%+0.79%-0.78%-87.26%NICXFNicox0.00%0.00%0.00%+20.00%-31.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTAIBioXcel Therapeutics4.4519 of 5 stars3.35.00.04.52.91.70.6EXOZeXoZymesN/AN/AN/AN/AN/AN/AN/AN/AIGMSIGM Biosciences4.5487 of 5 stars3.03.00.04.63.83.31.3NICXFNicoxN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTAIBioXcel Therapeutics 2.67Moderate Buy$39.75881.48% UpsideEXOZeXoZymes 0.00N/AN/AN/AIGMSIGM Biosciences 1.90Reduce$5.50333.07% UpsideNICXFNicox 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest NICXF, BTAI, EXOZ, and IGMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.008/26/2025BTAIBioXcel TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/21/2025NICXFNicoxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/15/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTAIBioXcel Therapeutics$2.27M28.56N/AN/A($6.73) per share-0.60EXOZeXoZymes$70K1,162.61N/AN/A$0.86 per share11.28IGMSIGM Biosciences$145.05M0.53N/AN/A$1.67 per share0.76NICXFNicox$5.52M3.75N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTAIBioXcel Therapeutics-$59.60M-$12.64N/AN/AN/A-5,869.82%N/A-134.45%11/13/2025 (Estimated)EXOZeXoZymes-$5.86MN/A0.00∞N/AN/A-134.50%-81.63%N/AIGMSIGM Biosciences-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%11/14/2025 (Estimated)NICXFNicox-$29.25MN/A0.00∞N/AN/AN/AN/A10/16/2025 (Estimated)Latest NICXF, BTAI, EXOZ, and IGMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BTAIBioXcel Therapeutics-$2.30-$2.45-$0.15-$2.45$0.21 million$0.12 million8/12/2025Q2 2025EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A7/31/2025Q2 2025IGMSIGM Biosciences-$0.30$1.58+$1.88$1.58$3.20 million$143.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/ANICXFNicoxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTAIBioXcel TherapeuticsN/A0.760.74EXOZeXoZymes0.016.196.19IGMSIGM BiosciencesN/A17.6617.66NICXFNicoxN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTAIBioXcel Therapeutics30.68%EXOZeXoZymesN/AIGMSIGM Biosciences42.79%NICXFNicoxN/AInsider OwnershipCompanyInsider OwnershipBTAIBioXcel Therapeutics21.20%EXOZeXoZymes72.41%IGMSIGM Biosciences57.00%NICXFNicoxN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTAIBioXcel Therapeutics9016.01 million12.62 millionOptionableEXOZeXoZymes298.39 million2.31 millionN/AIGMSIGM Biosciences19060.29 million25.93 millionOptionableNICXFNicox2868.92 millionN/ANot OptionableNICXF, BTAI, EXOZ, and IGMS HeadlinesRecent News About These CompaniesNicox glaucoma drug meets requirements for US and China approvalsAugust 22, 2025 | thepharmaletter.comTNicox plans filings for glaucoma after phase 3 winAugust 22, 2025 | pharmaphorum.comPPositive Outlook for Nicox SA Driven by Successful NCX 470 Trial and Strategic PartnershipsAugust 21, 2025 | tipranks.comNicox Extends Existing Flexible Equity FinancingAugust 8, 2025 | uk.finance.yahoo.comNicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in JapanAugust 5, 2025 | uk.finance.yahoo.comNicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470July 21, 2025 | ophthalmologytimes.comONicox SA’s Strategic Developments and Promising Trials Justify Buy RatingJuly 17, 2025 | tipranks.comNicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed TerritoriesJuly 17, 2025 | taiwannews.com.twTNicox S.A. (NICXF) Stock Price, Quote, News & AnalysisJuly 1, 2025 | seekingalpha.comNicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertensionJune 30, 2025 | ophthalmologytimes.comONicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical TrialJune 30, 2025 | manilatimes.netMNicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representativeJune 6, 2025 | santelog.comSNICOX SA: Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in JapanMay 27, 2025 | finanznachrichten.deNicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in JapanMay 27, 2025 | finance.yahoo.comNicox releases results from Whistler phase 3b trial in IOP lowering eye dropsMay 15, 2025 | ophthalmologytimes.comONicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma TrialMay 14, 2025 | finance.yahoo.comNicOx S.A.May 10, 2025 | barrons.comNicox Provides Full Year 2024 Financial ResultsApril 30, 2025 | finance.yahoo.comNicox announces last patient completed final visit in Whistler Phase 3b clinical trialMarch 24, 2025 | ophthalmologytimes.comONICOX SA: Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma TrialMarch 19, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNICXF, BTAI, EXOZ, and IGMS Company DescriptionsBioXcel Therapeutics NASDAQ:BTAI$4.05 -0.05 (-1.22%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.89 -0.16 (-4.05%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.eXoZymes NASDAQ:EXOZ$9.70 0.00 (0.00%) As of 08/28/2025eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.IGM Biosciences NASDAQ:IGMS$1.27 0.00 (0.00%) As of 08/14/2025IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Nicox OTCMKTS:NICXF$0.30 0.00 (0.00%) As of 08/27/2025Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
